| Title |
Does analgesic overuse matter? Response to OnabotulinumtoxinA in patients with chronic migraine with or without medication overuse
|
|---|---|
| Published in |
SpringerPlus, October 2015
|
| DOI | 10.1186/s40064-015-1386-8 |
| Pubmed ID | |
| Authors |
Fayyaz Ahmed, Hassan W. Zafar, Alina Buture, Modar Khalil |
| Abstract |
Chronic migraine affects 2 % of the population and has substantial impact on quality of life and considerable burden on healthcare resources. 50-80 % patients with chronic migraine have excessive consumption of analgesic medications. Withdrawal of analgesics is often advised before commencing preventive treatments. However, some headache experts recommend preventive treatments alongside analgesic withdrawal. 434 patients with chronic migraine attending the Hull Headache Clinic who received OnabotulinumtoxinA as preventive treatment were stratified to those with or without analgesic overuse. Data was collected through a dedicated headache diary and analysed for headache and migraine days reduction and for an increment in headache-free days in the month post treatment. The data shows no difference in the therapeutic outcome in patients with or without analgesic overuse with substantial reduction in headache and migraine days and an increment in headache-free days in both groups in a real-life clinical setting. OnabotulinumtoxinA is equally effective in patients with chronic migraine with or without analgesic overuse. |
Mendeley readers
The data shown below were compiled from readership statistics for 25 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Denmark | 1 | 4% |
| Unknown | 24 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 6 | 24% |
| Student > Master | 5 | 20% |
| Researcher | 3 | 12% |
| Student > Postgraduate | 3 | 12% |
| Student > Doctoral Student | 2 | 8% |
| Other | 4 | 16% |
| Unknown | 2 | 8% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 52% |
| Neuroscience | 3 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 8% |
| Psychology | 1 | 4% |
| Nursing and Health Professions | 1 | 4% |
| Other | 2 | 8% |
| Unknown | 3 | 12% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 January 2018.
All research outputs
#2,432,951
of 22,925,760 outputs
Outputs from SpringerPlus
#148
of 1,850 outputs
Outputs of similar age
#35,897
of 278,905 outputs
Outputs of similar age from SpringerPlus
#14
of 122 outputs
Altmetric has tracked 22,925,760 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,850 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 278,905 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 122 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.